Protagonist Therapeutics (PTGX) Accounts Payables (2015 - 2026)

Protagonist Therapeutics has disclosed Accounts Payables across 12 years of filings, most recently posting $17.5 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $17.5 million, up 47.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.5 million (up 47.69% YoY), and the FY2025 annual result was $5.3 million, up 230.59% from the prior year.
• Accounts Payables came in at $17.5 million for Q1 2026 at Protagonist Therapeutics, up from $5.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $32.9 million in Q1 2022 to a low of $1.4 million in Q2 2022.
• The 5-year median for Accounts Payables is $4.7 million (2022), against an average of $9.6 million.
• Across the five-year window, Accounts Payables tumbled 92.97% in 2022 and soared 431.81% in 2023, its largest moves.
• Protagonist Therapeutics' Accounts Payables stood at $3.6 million in 2022, then jumped by 431.81% to $19.4 million in 2023, then sank by 91.66% to $1.6 million in 2024, then soared by 230.59% to $5.3 million in 2025, then jumped by 227.61% to $17.5 million in 2026.
• The last three Accounts Payables figures came in at $17.5 million (Q1 2026), $5.3 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.